insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

ACRX · Acelrx Pharmaceuticals Inc - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$1.65M-$1.80M$1.50M$1.17M-$2.05M$1.91M$1.43M-
SG&A$2.30M-$1.62M$2.19M$1.77M-$1.70M$2.36M$2.80M-
Total Operating Expenses$3.95M-$3.42M$3.69M$2.94M-$3.75M$4.27M$4.24M-
D&A--------$0-
Operating Income($2.92M)-($3.42M)($4.27M)--($1.42M)($3.83M)--
Interest Expense------$0$15.0K$0-
Income Tax------$0$0--
Net Income($2.56M)-($4.44M)($3.49M)($2.59M)-($3.35M)($3.83M)($3.95M)-
EPS - Basic($0.04)-($0.11)($0.10)($0.10)-($0.13)($0.15)($0.16)-
EPS - Diluted----($0.16)-----

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$3.82M$5.89M$3.46M$6.79M$5.39M$8.86M$11.12M$13.42M$12.12M$5.72M
Accounts Receivable----------
Inventory----------
Accounts Payable$927.0K$544.0K$526.0K$835.0K$326.0K$670.0K$396.0K$808.0K$1.27M$1.34M
Current Assets$21.34M$20.90M$21.92M$7.70M$6.18M$9.42M$12.20M$16.04M$19.95M$11.56M
Total Assets$30.16M$29.72M$30.74M$16.52M$14.99M$18.24M$21.01M$24.86M$28.77M$20.39M
Current Liabilities$4.03M$3.81M$3.21M$2.63M$1.99M$2.65M$2.76M$3.27M$3.34M$4.51M
Long-term Debt----------
Total Liabilities$11.68M$12.68M$11.56M$9.89M$9.40M$10.23M$11.37M$12.13M$12.44M$6.29M
Stockholders' Equity$18.48M$17.04M$19.18M$6.63M$5.60M$8.00M$9.64M$12.73M$16.33M$14.11M
Retained Earnings($474.08M)($471.52M)($467.75M)($463.31M)($459.82M)($457.23M)($455.36M)($452.01M)($448.18M)($444.23M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($3.40M)---($3.47M)---($2.88M)-
Investing Cash Flow($2.71M)---$0---($2.73M)-
Financing Cash Flow$4.04M---($5.0K)---$12.01M-
CapEx--------$0-
Free Cash Flow--------($2.88M)-

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income--------0.73-
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-8.5%--14.4%-21.1%-17.3%--16.0%-15.4%-13.7%-
Return on equity-13.8%--23.1%-52.6%-46.3%--34.8%-30.1%-24.2%-
Return on invested capital----------
Liquidity
Current ratio5.305.496.832.933.113.564.424.905.972.56
Quick ratio5.305.496.832.933.113.564.424.905.972.56
Cash ratio0.951.551.082.582.713.354.024.103.631.27
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage--------255.1x--
Equity multiplier1.631.741.602.492.682.282.181.951.761.45
Liabilities / Assets0.390.430.380.600.630.560.540.490.430.31
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)---141.7%-11.6%------
Net income growth (YoY)1.4%--32.3%8.8%34.4%--147.1%12.4%--
EPS growth (YoY)----------
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)230.0%112.9%98.9%-47.9%-65.7%-43.3%-47.3%22.2%--35.3%

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing ACELRX PHARMACEUTICALS INC against the 5 most active filers in the same SIC group.